Announcements
- Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
- Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
- Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
- Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
- Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
- Cara Therapeutics Reports Third Quarter 2023 Financial Results
- Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
- Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
- Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
More ▼
Key statistics
On Thursday, Cara Therapeutics Inc (0HTC:LSE) closed at 0.6886, 37.73% above the 52 week low of 0.50 set on Jan 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | 12.28 |
Offer | -- |
Previous close | 0.6886 |
Average volume | 8.92k |
---|---|
Shares outstanding | 54.66m |
Free float | 46.69m |
P/E (TTM) | -- |
Market cap | 40.00m USD |
EPS (TTM) | -2.19 USD |
Data delayed at least 20 minutes, as of Apr 18 2024 19:08 BST.
More ▼